Individual peculiarities of patients with law back pain are important when administering non-steroidalanti-inflammatory drugs
In the article, we present the data on the evaluation of the genetic polymorphism of the CYP2C9 gene among patients with back pain of different localization, the identification of the analgesic effect in response to NSAIDs (ketorolac, meloxicam, celecoxib), and the risk of side effects in the presence of mutant genes.The genetic analysis of the polymorphism of the CYP2C9 gene showed that for the CYP2C9 marker (Arg144Cys), the mutant gene was only detected in the heterozygous state in 20.4% of patients with back pain. For the CYP2C9 marker (Ile359Leu), the mutation was also observed only in the hetero- zygous state in 12% of patients.When studying the pain dynamics on the VAS scale, in patients with the presence of mutant genes, the best dynamics was observed only in the case of the CYP2C9 marker (Ile369Leu) during 1-30 days, which can be explained by elevated drug concentrations in the plasma. These patients are at a potential risk of side effects with prolonged intake of NSAIDs.